Renal pelvis neoplasm

Summary

Renal pelvis neoplasm (MONDO:0003719) is a cancer and 2 clinical trials. Top therapeutic interventions include cisplatin and enfortumab vedotin. A subtype of kidney neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	renal pelvis neoplasm
Mondo ID	MONDO:0003719
DOID	DOID:5977
NCIT	C8404
SNOMED CT	126881002
UMLS	C0346260
MedGen	138049
Anatomy (UBERON)	UBERON:0001224
Is cancer (heuristic)	yes

Also known as: kidney pelvis neoplasm · kidney pelvis tumor · kidney pelvis tumour · neoplasm of kidney pelvis · neoplasm of renal pelvis · neoplasm of the kidney pelvis · neoplasm of the renal pelvis · renal pelvis neoplasm · renal pelvis neoplasm (disease) · renal pelvis tumor · renal pelvis tumour · tumor of kidney pelvis · tumor of renal pelvis · tumor of the kidney pelvis · tumor of the renal pelvis · tumour of kidney pelvis · tumour of renal pelvis · tumour of the kidney pelvis · tumour of the renal pelvis

Disease family

This is a subtype of kidney neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › kidney neoplasm › renal pelvis neoplasm

Related subtypes (7): kidney hemangiopericytoma, kidney cancer, mixed epithelial stromal tumor of the kidney, kidney benign neoplasm, childhood kidney neoplasm, multiloculated renal cyst, mesonephric neoplasm

Subtypes (3): renal pelvis papillary tumor, benign neoplasm of renal pelvis, malignant renal pelvis neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03219333	PHASE2	COMPLETED	A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03288545	PHASE1/PHASE2	TERMINATED	A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1
ENFORTUMAB VEDOTIN	4	1